Life sciences organizations are entering a new phase of AI adoption. The focus is shifting from experimentation and proof-of-concepts to enterprise-scale deployment across research, clinical development, manufacturing, quality, regulatory affairs and commercial operations. As organizations seek measurable business outcomes, executive leaders are making critical decisions about which AI capabilities to build internally, which to source from strategic partners and how to create scalable operating models that balance innovation, compliance and cost efficiency. This session examines where pharmaceutical, biotechnology and medical device companies are expected to invest through 2027 and how sourcing strategies are evolving to support AI-enabled transformation. Industry leaders will discuss emerging demand patterns, the rise of AI-native platforms, changing service provider roles and the growing importance of ecosystem partnerships among life sciences firms, hyperscalers, software vendors and specialized AI providers. Attendees will gain practical insight into the capabilities and partnerships likely to capture the greatest share of enterprise spending as AI becomes embedded across the life sciences value chain.